ArticleMolecular & cellular proteomics : MCP2013
The human leukocyte antigen-presented ligandome of B lymphocytes.
Article in Molecular & cellular proteomics : MCP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 104 citations in OpenAlex.
- Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire.Science advances · 2026Article
- A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.Blood · 2026Article
- Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics.Journal for immunotherapy of cancer · 2026Article
- CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.Science advances · 2025Article
- Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.Nature biotechnology · 2023Article
- Human T cells recognize HLA-DP-bound peptides in two orientations.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.International journal of hematology · 2022Review
- Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.Journal for immunotherapy of cancer · 2022Article
- Article
- CAMAP: Artificial neural networks unveil the role of codon arrangement in modulating MHC-I peptides presentation.PLoS computational biology · 2021Article
- Retinal Proteomics of a Mouse Model of Dystroglycanopathies Reveals Molecular Alterations in Photoreceptors.Journal of proteome research · 2021Article
- Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.iScience · 2021Article
- HLA Class II Presentation Is Specifically Altered at Elevated Temperatures in the B-Lymphoblastic Cell Line JY.Molecular & cellular proteomics : MCP · 2021Article
- Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome.Journal of proteome research · 2021Article
- Solving an MHC allele-specific bias in the reported immunopeptidome.JCI insight · 2020Article
- Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.The Journal of clinical investigation · 2020Article
- The HLA A03 Supertype and SeveralJournal of virology · 2020Article
- Review
- Murine xenograft bioreactors for human immunopeptidome discovery.Scientific reports · 2019Article
- Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer.Oncoimmunology · 2019Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptides presented by human leukocyte antigen (HLA) molecules on the cell surface play a crucial role in adaptive immunology, mediating the communication between T cells and antigen presenting cells. Knowledge of these peptides is of pivotal importance in fundamental studies of T cell action and in cellular immunotherapy and transplantation. In this paper we present the in-depth identification and relative quantification of 14,500 peptide ligands constituting the HLA ligandome of B cells. This large number of identified ligands provides general insight into the presented peptide repertoire and antigen presentation. Our uniquely large set of HLA ligands allowed us to characterize in detail the peptides constituting the ligandome in terms of relative abundance, peptide length distribution, physicochemical properties, binding affinity to the HLA molecule, and presence of post-translational modifications. The presented B-lymphocyte ligandome is shown to be a rich source of information by the presence of minor histocompatibility antigens, virus-derived epitopes, and post-translationally modified HLA ligands, and it can be a good starting point for solving a wealth of specific immunological questions. These HLA ligands can form the basis for reversed immunology approaches to identify T cell epitopes based not on in silico predictions but on the bona fide eluted HLA ligandome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.